MedPAC Considers Value-Based, Reference Pricing, Doctor Pay Changes

By John Wilkerson / October 7, 2021 at 6:53 PM
Congressional Medicare advisers on Thursday (Oct. 7) began discussing policies for controlling drug prices, primarily in Part B, that include setting value-based payments for first-in-class drugs, setting prices for drugs with alternative treatments using reference pricing and changing the provider reimbursement formula in Part B for administering drugs. The Medicare Payment Advisory Commission (MedPAC) also considered referencing international prices for a one-time rebasing of prices in Part B, but that policy got less attention than domestic reference pricing schemes, such...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.